GENETICS OF OSTEOPOROSIS IN OLD ORDER AMISH

老阿米什人骨质疏松症的遗传学

基本信息

  • 批准号:
    6121420
  • 负责人:
  • 金额:
    $ 6.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-12-01 至 1999-11-30
  • 项目状态:
    已结题

项目摘要

Osteoporosis is a major public health problem in developed countries. By the year 2050, it is estimated that the incidence of this debilitating disorder will significantly increase both in terms of the numbers of women and men affected and in the escalating cost of patient care. Recent studies indicate that there is a strong genetic component in the development of osteoporosis. The studies also indicate that osteoporosis is a complex disorder with several genes interacting to set the stage for bone loss with advancing age and in certain younger individuals. The Old Order Amish of Lancaster County, Pennsylvania, are a homogeneous population that is ideal for the identification of osteoporosis susceptibility genes by candidate gene analysis and positional cloning methodology. Osteoporotic probands have been identified by history of vertebral or hip fracture and by bone mineral density (BMD) measurements. In addition, the serum markers procollagen type I carboxyl terminal peptide (PICP), osteocalcin, 25 hydroxy vitamin D, and the urinary marker deoxypyridinoline (DPD), have been analyzed. During the current reporting period, the data including BMD measurements and serum and urinary bone metabolism markers have been statistically analyzed for possible correlations for 135 participants. The defined osteoporotic population exhibited differences compared to normal cohorts in terms of BMD, DPD and PICP values. The serum markers (osteocalcin and 25 hydroxy vitamin D) showed no mean differences between osteoporotic and normal participants. Between the two groups, there were no significant age or gender differences. Within the osteoporotic group, however, age and gender differences were apparent with men and women exhibiting differing rates of bone loss (as measured by BMD and DPD), and differing ages of diagnosis. With the two study populations phenotypically defined, the stage is now set for an initial screening of candidate gene polymorphisms. The polymorphisms to be studied include those of the vitamin D receptor, estrogen receptor alpha and beta, as well as, type I collagen. CORE LABORATORY ONLY; NO INPATIENT DAYS OR OUTPATIENT VISITS.
骨质疏松症是发达国家的一个主要公共卫生问题。据估计,到2050年,这种使人衰弱的疾病的发病率将显著增加,无论是受影响的妇女和男子的人数,还是病人护理费用的不断上升。最近的研究表明,在骨质疏松症的发展中有很强的遗传成分。这些研究还表明,骨质疏松症是一种复杂的疾病,随着年龄的增长和某些年轻人,几个基因相互作用为骨质流失奠定了基础。宾夕法尼亚州兰开斯特县的旧秩序阿米什人是一个同质的群体,是通过候选基因分析和定位克隆方法鉴定骨质疏松症易感基因的理想人群。骨质疏松症先证者通过脊椎或髋部骨折史和骨矿物质密度(BMD)测量确定。此外,血清标志物I型前胶原羧基末端肽(PICP),骨钙素,25羟基维生素D,和尿标志物脱氧吡啶啉(DPD),进行了分析。在本报告期间,对135名参与者的数据(包括BMD测量和血清及尿液骨代谢标志物)进行了统计学分析,以确定可能的相关性。与正常人群相比,定义的骨质疏松人群在BMD、DPD和PICP值方面表现出差异。血清标志物(骨钙素和25羟基维生素D)显示,没有平均值之间的差异,骨质疏松症和正常参与者。两组之间没有明显的年龄或性别差异。然而,在骨质疏松组中,年龄和性别差异明显,男性和女性表现出不同的骨质流失率(通过BMD和DPD测量)和不同的诊断年龄。随着两个研究人群的表型定义,现在的阶段是候选基因多态性的初步筛选。待研究的多态性包括维生素D受体、雌激素受体α和β以及I型胶原蛋白的多态性。仅限核心实验室;无住院日或门诊访视。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAY Robert SHAPIRO其他文献

JAY Robert SHAPIRO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAY Robert SHAPIRO', 18)}}的其他基金

TERIPARATIDE (FORTEO) FOR INCREASING BONE MASS
用于增加骨量的特立帕肽 (Forteo)
  • 批准号:
    7604687
  • 财政年份:
    2006
  • 资助金额:
    $ 6.52万
  • 项目类别:
EFFECT OF MINOCYCLINE IN POSTMENOPAUSAL OSTEOPOROSIS
米诺环素对绝经后骨质疏松症的作用
  • 批准号:
    6121421
  • 财政年份:
    1998
  • 资助金额:
    $ 6.52万
  • 项目类别:
SKELETAL TURNOVER IN OSTEOGENESIS IMPERFECTA--EFFECT OF PAMIDRONATE THERAPY
成骨不全症的骨骼转换--帕米膦酸钠治疗的效果
  • 批准号:
    6281935
  • 财政年份:
    1998
  • 资助金额:
    $ 6.52万
  • 项目类别:
BONE MINERAL DENSITY--INFLUENCE OF AGE AND RACE
骨矿物质密度——年龄和种族的影响
  • 批准号:
    6121396
  • 财政年份:
    1998
  • 资助金额:
    $ 6.52万
  • 项目类别:
EFFECT OF MINOCYCLINE IN POSTMENOPAUSAL OSTEOPOROSIS
米诺环素对绝经后骨质疏松症的作用
  • 批准号:
    6281961
  • 财政年份:
    1998
  • 资助金额:
    $ 6.52万
  • 项目类别:
GENETICS OF OSTEOPOROSIS IN OLD ORDER AMISH
老阿米什人骨质疏松症的遗传学
  • 批准号:
    6281960
  • 财政年份:
    1998
  • 资助金额:
    $ 6.52万
  • 项目类别:
BONE MINERAL DENSITY--INFLUENCE OF AGE AND RACE
骨矿物质密度——年龄和种族的影响
  • 批准号:
    6281936
  • 财政年份:
    1998
  • 资助金额:
    $ 6.52万
  • 项目类别:
CORRELATION OF BMD WITH PARAMETERS OF SKELETAL TURNOVER--INFLUENCE OF AGE & RACE
BMD与骨骼转换参数的相关性——年龄的影响
  • 批准号:
    6252495
  • 财政年份:
    1997
  • 资助金额:
    $ 6.52万
  • 项目类别:
SKELETAL TURNOVER IN OSTEOGENESIS IMPERFECTA--EFFECT OF PAMIDRONATE THERAPY
成骨不全症的骨骼转换--帕米膦酸钠治疗的效果
  • 批准号:
    6252493
  • 财政年份:
    1997
  • 资助金额:
    $ 6.52万
  • 项目类别:
BONE MARROW OSTEOPROGENITOR CELLS IN TYPES I AND II OSTEOPOROSIS
I 型和 II 型骨质疏松症的骨髓骨祖细胞
  • 批准号:
    6252500
  • 财政年份:
    1997
  • 资助金额:
    $ 6.52万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.52万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
  • 批准号:
    10762827
  • 财政年份:
    2023
  • 资助金额:
    $ 6.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了